Pharmacological interventions for the correction of ion transport defect in cystic fibrosis

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 10, 2004, Pages 1465-1483

  Becq, Frédéric ^a   Mettey, Yvette ^b  

^a UNIVERSITÉ DE POITIERS   (France)

^b Lab de Pharm Galenique Biopharm   (France)

Author keywords

Amiloride sensitive Na+ channel (ENaC); Cystic fibrosis therapy; Cystic fibrosis transmembrane conductance regulator (CFTR) Cl channel; Epithelial K+ channels; Epithelial secretion; High throughput screening (HTS); Pharmacology; Polypeptides; Small molecules

Indexed keywords

1,3 DIALLYL 8 CYCLOPENTYLXANTHINE; 1,7 DIHYDRO 2 (PROPOXYPHENYL) 6H PURIN 6 ONE; 4 PHENYLBUTYRIC ACID; 8 CYCLOPENTYL 1,3 DIPROPYL 7 METHYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ACETAMIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; APIGENIN; ARYLBUTYRIC ACID DERIVATIVE; BUPHENYL; CAFFEINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHLORIDE; CHLORIDE CHANNEL; CURCUMIN; CYCLIC AMP; CYCLOHEXYLCAFFEINE; CYCLOPIAZONIC ACID; FLAVONE DERIVATIVE; GENISTEIN; GENTAMICIN; HALOTHANE; ISOFLAVONE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; QUINOLIZINE DERIVATIVE; SESQUITERPENE LACTONE DERIVATIVE; SODIUM CHLORIDE; THAPSIGARGIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

CELL MEMBRANE; CHLORIDE TRANSPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIGESTIVE SYSTEM; DRUG ABSORPTION; DRUG INDUSTRY; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; EPITHELIUM CELL; GENE MUTATION; GENITAL SYSTEM; HIGH THROUGHPUT SCREENING; HUMAN; MALE INFERTILITY; PANCREAS INSUFFICIENCY; PATENT; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFECTION; REVIEW; SWEATING;

EID: 5744227335     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.10.1465     Document Type: Review

References (99)

1. PILEWSKI JM, FRIZZELL RA: Role of CFTR in airway disease. Physiol. Rev. (1999) 79:215-255.
2. BARRETT KE, DHARMSATHAPHORN K: Mechanisms of Chloride Secretion in a Colonic Epithelial Cell Line. Lebenthal E, Duffey M (Eds). Raven, New York (1990):59-66.
3. + channel is made of three homologous subunits. Nature (1994) 367:463-467.
4. + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J. Clin. Invest. (1986) 78:1245-1252.
5. RIORDAN JR, ROMMENS JM, KEREM B et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (1989) 245:1066-1073.
6. HANRAHAN JW, GENTZSCH M, RIORDAN JR: The cystic fibrosis transmembrane conductance regulator (ABCC7). In: ABC Proteins: From Bacteria to Man. Holland IB, Cole S, Kuchler K, Higgins CF (Eds). Academic Press (2003):589-618.
7. - channel in CHO cells stably expressing the cystic fibrosis gene. Nature (1991) 352:628-631.
8. LINTON KJ, ROSENBERG MF, KERR ID, HIGGINS CF: Structure of ABC transporters. In: ABC Proteins: From Bacteria to Man. Holland IB, Cole S, Kuchler K, Higgins CF (Eds) Academic Press (2003):65-80.
9. SHEPPARD DN, WELSH MJ: Structure and function of the CFTR chloride channel. Physiol. Rev. (1999) 79:23-45.
10. SCHWIEBERT EM, BENOS DJ, EGAN ME, STUTTS J, GUGGINO WB: CFTR is a conductance regulator as well as a chloride channel. Physiol. Rev. (1999) 79:145-166.
11. GADSBY DC, NAIRN AC: Contol of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol. Rev. (1999) 79:77-107.
12. BECQ F, JENSEN TJ, CHANG X-B et al.: Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc. Natl. Acad. Sci. USA (1994) 91:9160-9164.
13. RATJEN F, DORING G: Cystic fibrosis. Lancet (2003) 361:681-689.
14. WELSH MJ, SMITH AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 73 1251-1254.
15. CHENG SH, GREGORY RJ, MARSHALL J et al.: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell (1990) 63:827-834.
16. GELMAN MS, KOPITO RR: Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. J. Clin. Invest. (2002) 110:1591-1597.
17. THOMAS PJ, SHENBAGAMURTHI P, SONDEK J, HULLIHEN JM, PEDERSEN PL: The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. J. Biol. Chem. (1992) 267:5727-5730.
18. WARD CL, OMURA S, KOPITO RR: Degradation of CFTR by the ubiquitin-proteasome pathway. Cell (1995) 83:122-127.
19. CUTTING GR, KASCH LM, ROSENSTEIN BJ et al.: A cluster of cystic fibrosis mutations in the first nucleotide binding fold domain of the cystic fibrosis conductance regulator protein. Nature (1990) 346:366-369.
20. LOGAN J, HIESTAND D, DARAM P et al.: Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J. Clin. Invest. (1994) 94:228-326.
21. POWELL K, ZEITLIN PL: Therapeutic approaches to repair defects in ΔF508 CFTR folding and cellular targeting. Ad. Drug Del. Rev. (2002) 54:1395-1408.
22. DALEMANS W, BARBRY P, CHAMPIGNY G et al.: Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature (1991) 354:526-528.
23. DRUMM ML, WILKINSON DJ, SMIT LS et al.: Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science (1991) 254:1797-1799.
24. MORELLO JP, PETAJA-REPO UE, BICHET DG, BOUVIER M: Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci. (2000) 21:466-469.
25. EIDELMAN O, GUAY-BRODER C, VAN GALEN PJ et al.: A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. Sci. USA (1992) 89 5562-5566.
26. GUAY-BRODER C, JACOBSON KA, BARNOY ZI et al.: A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator ΔF508 mutation. Biochemistry (1995) 34:9079-9087.
27. JACOBSON KA, GUAY-BRODER C, VAN GALEN PJ et al.: Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors. Biochemistry (1995) 34 9088-9094.
28. ARISPE N, MA J, JACOBSON KA, POLLARD HB: Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). J. Biol. Chem. (1997) 273:5727-5734.
29. COHEN BE, LEE G, JACOBSON KA et al.: 8-cyclopentyl-1-3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry (1997) 36:6455-6461.
30. CHAPPE V, METTEY Y, VIERFOND J-M et al.: Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br. J. Pharmacol. (1998) 123 683-693.
31. McCARTY N, STANDART TA, TERESI M et al.: A Phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Ped. Pulm. (2002) 33:90-98.
32. DENNING GM, ANDERSON MP, AMARA JF et al.: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (1992) 358:761-764.
33. EDINGTON BV, WHELAN SA, HIGHTOWER LE: Inhibition of heat shock (stess) protein induction by deuterium oxide and glycerol: additional support for the abnormal protein hypothesis of induction. J. Cell Physiol. (1989) 139:219-228.
34. BROWN CR, HONG-BROWN LQ, BIWERSI J, VERKMAN AS, WELCH WJ: Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stess Chap. (1996) 1:117-125.
35. HOWARD M, FISCHER H, ROUX J et al.: Mammalian osmolytes and S-nitrosoglutathione promote ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) protein maturation and function. J. Biol. Chem. (2003) 278:35159-35167.
36. ZHANG XM, WANG XT, YUE H et al.: Organic solutes rescue the functional defect in ΔF508 cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. (2003) 278:51232-51242.
37. HAWORTH JC, DILLING LA, SURTEES RA et al.: Symptomatic and asymptomatic methylenetetrahydrofolate reductase deficiency in two adult brothers. Am. J. Med. Genet. (1993) 45:572-576.
38. CHENG SH, FANG SL, ZABNER J et al.: Functional activation of the cystic fibrosis trafficking mutant ΔF508-CFTR by overexpression. Am. J. Physiol. (1995) 268:615-624.
39. RUBENSTEIN RC, EGAN ME, ZEITLIN PL: In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF508-CFTR. J. Clin. Invest. (1997) 100:2457-2465.
40. RUBENSTEIN RC, ZEITLIN PL: Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR. Am. J. Phyiol. (2000) 278:259-267.
41. RUBENSTEIN RC, ZEITLIN PA: A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in ΔF508-homozygous cystic fibrosis patients. Am. J. Respir. Crit. Care Med. (1998) 157:484-490.
42. ZEITLIN PA, DIENER-WEST M, RUBENSTEIN RC et al.: Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol. Ther. (2002) 6 119-126.
43. BEDWELL DM, KAENJAK A, BENOS DJ et al.: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. (1997) 3:1280-1284.
44. WILCHANSKI M, YAHAV Y, YAACOV Y et al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. (2003) 349 1433-1441.
45. EGAN ME, GLOCKNER-PAGEL J, AMBROSE CA et al.: Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med. (2002) 8:485-492.
46. EGAN ME, PEARSON M, WEINER SA et al.: Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science (2004) 304:600-602.
47. LYTTON J, WESTLIN M, HANLEY MR: Thapsigargin inhibits the sarcoplasmic or endoplasmi reticulum Ca-ATPase family of calcium pumps. J. Biol. Chem. (1991) 266:17067-17071.
48. BECQ F, METTEY Y, GRAY MA et al.: Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic cibrosis chloride channel. J. Biol. Chem. (1999) 274 27415-27425.
49. MARIVINGT-MOUNIR C, NOREZ C, DERAND R et al.: Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. J. Med. Chem. (2004) 47:962-972.
50. DERAND R, BULTEAU-PIGNOUX L, METTEY Y et al.: Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation. Am. J. Physiol. (2001) 281 1657-1666.
51. DORMER R L, DERAND R, MCNEILLY C et al.: Correction of delF508-CFTR activity with benzoquinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J. Cell Sci. (2001) 114:4073-4081.
52. STRATFORD FL, PEREIRA MM, BECQ F, MCPHERSON MA, DORMER RL: Benzo(c)quinolizinium drugs inhibit degradation of ΔF508-CFTR cytoplamsic domain. Biochem. Biophys. Res. Commun. (2003) 300 524-530.
53. MCPHERSON MA, PEREIRA MM, LLOYD-MILLS C, MURRAY KJ, DORMER RL: A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein. FEBS Lett. (1999) 464:48-52.
54. ILLEK B, FISCHER H, SANTOS GF, WIDDICOMBE JH, MACHEN TE, REENSTRA WW: cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am. J. Physiol. (1995) 268 886-893.
55. ILLEK B, FISCHER H, MACHEN T: Alternate stimulation of apical CFTR by genistein in epithelia. Am. J. Physiol. (1996) 270 265-275.
56. DERAND R, BULTEAU-PIGNOUX L, BECQ F: The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory genistein binding site. J. Biol. Chem. (2002) 277 35999-36004.
57. MELIN P, THOREAU V, NOREZ C, BILAN F, KITZIS A, BECQ F: The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem. Pharmacol. (2004) 67:2187-2196.
58. SPRINGSTEEL MF, GALIETTA LJ, MAT et al.: Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bio. Med. Chem. (2003) 11:4113-4120.
59. CACI E, FOLLI C, ZEGARRA-MORAN O et al.: CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am. J. Physiol. (2003) 285 180-188.
60. DUSZYK M, MACVINISH L, CUTHBERT AW: Phenanthrolines - a new class of CFTR chloride channel openers. Br. J. Pharmacol. (2001) 134:853-864.
61. CUTHBERT AW: Benzoquinolines and chloride secretion in routine colonic epithelium. Br. J. Pharmacol. (2003) 138 1528-1534.
62. CUTHBERT AW, MACVINISH LJ: Mechanisms of anion secretion in Calu-3 human airway epithelial cells by 7,8-benzoquinoline. Br. J. Pharmacol. (2003) 140:81-90.
63. SZKOTAK AJ, MURTHY M, McVINISH et al.: 4-chlorobenzo[F]isoquinoline (CBIQ) activates CFTR chloride channels and KCNN4 potassium channels in Calu-3 human airway epithelial cells. Br.J. Pharmacol. (2004) 142:531-542.
64. GALIETTA LJV, SPRINGSTEEL MF, EDA M et al.: Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem. (2001) 276:19723-19728.
65. MA T, VETRIVEL L, YANG H et al.: High-affiniry activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol. Chem. (2002) 277:37235-37241.
66. YANG H, SHELAT AA, GUY RK et al.: Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating. J. Biol. Chem. (2003) 278:35079-35085.
67. SAMMELSON RE, MA T, GALIETTA LJV, VERKMAN AS, KURTH MJ: 3-(2-benzyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bio. Med. Chem. Lett. (2003) 13:2509-2512.
68. - secretion by chlorzoxazone. J. Pharm. Exp. Ther. (2000) 292:778-787.
69. - secretion. Am. J. Physiol. (1997) 272 976-988.
70. - secretion by benzimidazolones. II. Coordinate regulation of apical GCl and basolateral GK. Am. J. Physiol. (1996) 271:785-795.
71. + channels in airway epithelia. II. Role in Cl secretion and evidence for two types of K channels. Am. J. Physiol. (1990) 258:343-348.
72. - secretion in human airway epithelia. Am. J. Respir. Cell Molec. Biol. (2000) 23:283-289.
73. BERNARD K, BOGLIOLO S, SORIANI O, EHRENFELD J: Modulation of calcium-dependent chloride secretion by basolateral SK4-like channels in a human bronchial cell line. J. Membr. Biol. (2003) 196 15-31.
74. + channels in human normal and cystic fibrosis airway epithelia. Pediatr. Res. (2003) 53:608-618.
75. + channels. Am. J. Physiol. (2000) 278:570-581.
76. JOINER WJ, WANG LY, TANG MD, KACZMAREK LK: hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc. Natl. Acad. Sci. USA (1997) 94:11013-11018.
77. GRIBKOFF VK, CHAMPIGNY G, BABRY P, DWORETZKY SI, MEANWELL NA, LAZDUNSKI M: The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. (1994) 269 10983-10986.
78. AL-NAKKASH L, HU S, LI M, HWANG T-C: A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogues. J. Pharm. Exp. Ther. (2001) 296:464-472.
79. + channel. Am. J. Physiol. (1996) 271:775-784.
80. DERAND R, BULTEAU-PIGNOUX L, BECQ F: Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J. Membr. Biol. (2003) 194:109-117.
81. SINGH S, SYME CA, SINGH AK, DEVOR DC, BRIDGES RJ: Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J. Pharm. Exp. Ther. (2001) 296:600-611.
82. + channels by novel benzimidazolone. Eur. J. Pharmacol. (1994) 251:53-59.
83. GRAHAM A, HASANI A, ALTON EW et al.: No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur. Respir. J. (1993) 6:1243-1248.
84. PONS G, MARCHAND MC, D'ATHIS P et al.: French multicenter randomised double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr. Pulmonol. (2000) 30:25-31.
85. RODGERS HC, KNOX AJ: The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur. J. Respir. (1999) 14:693-696.
86. + transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am. J. Physiol. (2001) 281:16-23.
87. HWANG TH, SCHWIEBERT EM, GUGGINO WB: Apical and basolateral ATP stimulate tracheal epithelial chloride secretion via multiple purinergic receptors and signalling pathways. Am. J. Physiol. (1996) 270:1611-1623.
88. CLARK LL, GRUBB BR, YANKASKAS JR, COTTON CU, McKENZIE A, BOUCHER RC: Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. Proc. Natl. Acad. Sci. USA (1994) 91 479-483.
89. RUDOLF MT, DINKEL C, TRAYNOR-KAPLAN AE, SCHULTZ C: Antagonists of myo-Inositol 3,4,5,6-tetrakisphophate allow repeated epithelial chloride secretion. Bioorg. Med. Chem. (2003) 11 3315-3329.
90. VAJANAPHANICH M, SCHULTZ C, RUDOLF MT et al.: Long-term uncoupling ofchloride secretion from intracellular calcium levels by Ins(3,4,5,6)P4. Nature (1994) 371:711-714.
91. - secretion in T84 cells. Am. J. Physiol. (1993) 264:671-676.
92. ZEITLIN PL, BOYLE MP, GUGGINO WB, MOLINA L: A Phase I trial of intranasal Moli1901 for cystic fibrosis. Chest (2004) 125 143-149.
93. CHANG XB, CUI L, HOU YX et al.: Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. Mol. Cell. (1999) 4:137-142.
94. OWSIANIK G, CAO L, NILIUS B: Rescue of functional D508-CFTR channels by co-expression with truncated CFTR constructs in COS-1 cells. FEBS Lett (2003) 554:173-178.
95. ZERANGUE N, SCHWAPPACH B, JAN YN, JAN LY: A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K(ATP) channels. Neuron (1999) 22:537-548.
96. XIE J, ADAM LM, ZHAO J, GERKEN TA, DAVIS PB, MA J: A short segment of the R domain of cystic fibrosis transmembrane conductance regulator contains channel stimulatory and inhibitory activities that are separable by sequence modification. J. Biol. Chem (2002) 277 23019-23027.
97. VERKMAN AS: Drug discovery in academia. Am. J. Physiol. (2004) 286:465-474.
98. ARIDOR M, HANNAN LA: Traffic jam: A compendium of human diseases that affect intracellular transport processes. Traffic (2000) 1:836-851.
99. ARIDOR M, HANNAN LA: Traffic jam II: An update of diseases of intracellular transport. Traffic (2002) 3:781-790.